Sector: Health Care
Director information for EXELIXIS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Amy C. Peterson, M.D. | Former Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer | [] | [] | 2026 | |
| Brenda J. Hefti, J.D., Ph.D. | Senior Vice President and General Counsel | 52 | ["Ph.D. in Neuroscience from the University of Wisconsin, Madison","J.D. from the University of California School of Law","Experience in intellectual property and licensing","Negotiation experience with UCSF and pharmaceutical companies","Advisory experience on corporate governance, mergers and acquisitions, public company reporting, and private equity and debt financings"] | [] | 2026 |
| Christopher J. Senner | Executive Vice President and Chief Financial Officer | 58 | ["B.S. in Finance from Bentley College","Served as Vice President, Corporate Finance for Gilead Sciences, Inc.","Eighteen years at Wyeth in various financial roles","Chief Financial Officer of Wyeth’s U.S. pharmaceuticals business","Member of the board of directors of Quince Therapeutics, Inc."] | [] | 2026 |
| Dana T. Aftab, Ph.D. | Executive Vice President, Research and Development | 63 | ["B.A. and Ph.D. in pharmacology from the University of California, Santa Barbara and Yale University","Led research efforts to drive innovation and expand product pipeline at Exelixis","Started in Exelixis’ Drug Discovery organization in 1998","Held senior scientist positions at several biotech start-ups"] | [] | 2026 |
| David E. Johnson | Independent Director | 43 | ["Expertise in strategic capital allocation","Experience as an investor and director for various life sciences companies"] | ["Audit Committee","Research & Development Committee"] | 2026 |
| George Poste, D.V.M., Ph.D., FRS | Independent Director; Chief Scientist, Complex Adaptive Systems Initiative | 81 | ["Training as a scientist","Knowledge and experience in life sciences, healthcare, and pharmaceutical industries","Broad leadership experience from various boards","Knowledge and experience with policymaking, regulatory issues, and governmental matters"] | ["Research & Development Committee (Chair)","Risk Committee"] | 2026 |
| Jack L. Wyszomierski | Independent Director | 70 | ["extensive financial reporting, accounting, and finance experience","experience in the healthcare and life sciences industries","Chair of the Audit Committee","previous roles at VWR International, LLC and Schering-Plough Corporation","member of the board of directors of XOMA Corporation and SiteOne Landscape Supply, Inc."] | ["Audit Committee","Governance Committee"] | 2026 |
| Jeffrey J. Hessekiel, J.D. | Former Executive Vice President and General Counsel | [] | [] | 2026 | |
| Julie Anne Smith | Independent Director; Former Chief Executive Officer, Nuvig Therapeutics, Inc. | 55 | ["Knowledge and experience in biotechnology, healthcare, and pharmaceutical industries","Broad leadership experience as an executive in the pharmaceutical industry"] | ["Audit Committee","Compensation Committee (Chair)"] | 2026 |
| Maria C. Freire, Ph.D. | Independent Director | 71 | ["Training as a scientist","Knowledge and experience in U.S. and global public health","Experience in the biopharmaceutical industry and government healthcare policymaking","Leadership experience in the public sector","Former President and Executive Director, Foundation for the National Institutes of Health","Former President and member of the board of directors of the Albert and Mary Lasker Foundation","Former President and CEO of the TB Alliance","Director of the Office of Technology Transfer at the National Institutes of Health"] | ["Governance Committee","Research & Development Committee"] | 2026 |
| Mary C. Beckerle, Ph.D. | Independent Director | 71 | ["Distinguished Professor of Biology and Oncological Sciences at the University of Utah","Chief Executive Officer of the Huntsman Cancer Institute from 2006 to 2025","Board member of Huntsman Corporation since 2011","Board member of Johnson & Johnson since 2015","Member of various scientific and advisory boards","NACD Corporate Governance Fellow","NACD Directorship 100 Honoree","Elected member of the National Academy of Sciences","Elected member of the American Philosophical Society","Elected member of the American Academy of Arts and Sciences","B.A. in Biology and Psychology (magna cum laude) from Wells College","Ph.D. in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder","Post-doctoral fellowship in Anatomy and Cell Biology at the University of North Carolina at Chapel Hill"] | ["Governance Committee","Research & Development Committee","Risk Committee"] | 2026 |
| Michael M. Morrissey, Ph.D. | President and Chief Executive Officer | 65 | ["President and Chief Executive Officer of Exelixis","Extensive qualifications in biotechnology, healthcare and pharmaceutical industries","Leadership background as an executive in the biotechnology industry","Author of scientific publications in medicinal chemistry and drug discovery","Inventor on 70 issued U.S. patents and 25 additional published U.S. patent applications","B.S. in Chemistry from the University of Wisconsin","Ph.D. in Chemistry from Harvard University"] | [] | 2026 |
| Robert (Bob) L. Oliver, Jr. | Executive Advisor | 67 | ["Leadership experience in pharmaceutical commercialization","Experience in financial strategy and business development","Various senior positions at Otsuka America Pharmaceutical, Inc.","Executive Advisor of CELLIX Biosciences","Board member of Neurotez, Inc. and Hyalo Technologies, LLC","B.A. from Rutgers University","M.B.A. from Saint Joseph’s University"] | ["Compensation Committee","Risk Committee"] | 2026 |
| S. Gail Eckhardt, M.D. | Independent Director | 68 | ["Skills as a physician and medical researcher","Leadership experience in drug development and translational medicine relative to oncology","Service on various public company boards and scientific or advisory boards"] | ["Compensation Committee","Research & Development Committee"] | 2026 |
| Stelios Papadopoulos, Ph.D. | Independent Chair of the Board | 77 | ["Training as a scientist","Knowledge and experience in biotechnology, healthcare and pharmaceutical industries","Broad leadership experience from service on various boards","Knowledge and experience with finance matters","Ability to bring historical knowledge and continuity to the Board"] | ["Audit Committee","Compensation Committee","Research & Development Committee"] | 2026 |
| Tomas J. Heyman | Independent Director | 70 | ["Expertise in corporate development","Significant leadership experience in the biopharmaceutical sector","Extensive experience serving on the boards of several public and private companies"] | ["Governance Committee","Risk Committee"] | 2026 |
